Elevated serum free light chains predict cardiovascular events in type 2 diabetes

Srikanth Bellary*, Jeffrey M. Faint, Lakhvir K. Assi, Colin A. Hutchison, Stephen J. Harding, Neil T. Raymond, Anthony H. Barnett

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review


OBJECTIVE: Elevated polyclonal serum immunoglobulin free light chains (FLCs; combined FLCκ+FLCλ [cFLC]) are associated with adverse clinical outcomes and increased mortality; we investigated cFLC and cardiovascular disease (CVD) events in type 2 diabetes. RESEARCH DESIGN AND METHODS: In a cohort study of 352 south Asian patients with type 2 diabetes, serum cFLC, high-sensitivity C-reactive protein (hsCRP), and standard biochemistry were measured. CVD events over 2 years were recorded and assessed usingmultiple logistic regression. RESULTS: cFLC levels were elevated significantly in 29 of 352 (8%) patients with CVD events during 2 years of follow-up (50.7 vs. 42.8mg/L; P = 0.004). Inmultivariate analysis, elevated cFLC (>57.2 mg/L) was associated with CVD outcomes (odds ratio 3.3 [95% CI 1.3-8.2]; P = 0.012) and remained significant after adjusting for age, albumin-to-creatinine ratio, diabetes duration, or treatment. CONCLUSIONS: cFLC elevation is a novel marker for CVD outcomes in type 2 diabetes that warrants further investigation. © 2014 by the American Diabetes Association.

Original languageEnglish
Pages (from-to)2028-2030
Number of pages3
JournalDiabetes Care
Issue number7
Early online date17 Apr 2014
Publication statusPublished - 31 Jul 2014


Dive into the research topics of 'Elevated serum free light chains predict cardiovascular events in type 2 diabetes'. Together they form a unique fingerprint.

Cite this